Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

Core Insights - Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing differentiated allogeneic cell therapies and genetic medicines for cancer and rare diseases [3] Company Overview - The company is developing investigational allogeneic CAR-T cell therapies targeting both solid tumors and hematologic cancers, as well as in vivo genetic medicines for patients with high unmet medical needs [3] - Poseida utilizes proprietary genetic editing platforms, including the non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ Site-Specific Gene Editing System, along with in-house GMP cell therapy manufacturing [3] - Strategic collaborations have been formed with Roche and Astellas to enhance the potential of cell therapies for cancer patients [3] Upcoming Events - The President and CEO, Kristin Yarema, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on July 9, 2024 [1] - A live webcast of the event will be available on Poseida's website, with a replay accessible for approximately 90 days post-presentation [2]